4.1 Massive Pulmonary Embolism & Acute Pulmonary Hypertension Crises

4.1 Massive Pulmonary Embolism & Acute Pulmonary Hypertension Crises

Clinical Scenario: A 58-year-old female on post-op day 3 following knee arthroplasty abruptly develops pleuritic chest pain, dyspnea, and syncope. Vital signs: BP 78/48 mmHg, HR 132 bpm, RR 34, SpO2 85% on 6 L/min cannula. Physical exam reveals marked jugular venous distention and loud P2. Bedside echocardiogram demonstrates right ventricular dilation, McConnell sign, and paradoxical septal flattening. High-sensitivity troponin I is 0.42 ng/mL and NT-proBNP is 1,850 pg/mL.

Risk Stratification & Clinical Definitions

The 2026 AHA/ACC clinical categories combine clinical severity with cardiopulmonary function:

• A: Asymptomatic, incidentally detected PE.
• B: Symptomatic PE with low clinical severity.
• C: Elevated clinical severity; C1 has normal RV/biomarker findings, C2 has one abnormal component, and C3 has both.
• D: Incipient cardiopulmonary failure, including transient hypotension or normotensive shock with impaired perfusion.
• E: Cardiopulmonary failure with persistent hypotension and shock, refractory shock, or cardiac arrest.

Traditional high-risk (massive) PE denotes hemodynamic instability. Intermediate-risk (submassive) PE lacks sustained hypotension but may have RV dysfunction and/or positive biomarkers. Intermediate-high risk combines elevated clinical risk with RV dysfunction and positive troponin; with elevated clinical risk, zero or one abnormal RV/biomarker component indicates intermediate-low risk. Reassess trajectory: a normal SBP does not exclude hypoperfusion.

PESI and Simplified PESI (sPESI)

The sPESI assigns one point each for age $>80$, cancer, chronic cardiopulmonary disease, HR $\ge 110$, SBP $<100$, and SpO2 $<90\%$. A score of 0 identifies a low-risk group; a positive score indicates increased risk, not a fixed individual mortality or automatic reperfusion indication. Outpatient treatment also requires clinical stability, acceptable bleeding risk, no other admission need, immediate anticoagulant access and rapid, reliable follow-up. Use Hestia criteria and clinical judgment alongside risk scores.

Diagnostic Biomarkers & Imaging of RV Strain

• Biomarkers: High-sensitivity cardiac troponin denotes RV microinfarction. BNP ($>100$ pg/mL) or NT-proBNP ($>600$ pg/mL) reflects acute myocardial wall tension.
• CT Pulmonary Angiography (CTPA): Diagnostic standard. An RV/LV diameter ratio $>0.9$ on transverse 4-chamber views confirms RV strain ($>1.0$ predicts high mortality). Contrast reflux into the IVC indicates severe RV failure.
• Transthoracic Echocardiography (TTE):
  • McConnell Sign: Akinesia of the mid-free RV wall with preserved apical contractility (highly specific for PE).
  • Paradoxical Septal Shift: Leftward bowing of the septum ("D-shaped" LV), restricting LV filling.
  • TAPSE: Tricuspid annular plane systolic excursion $<16$ mm marks significant longitudinal RV dysfunction.
  • Pulmonary Pressures: Tricuspid regurgitant velocity with estimated pulmonary artery systolic pressure (PASP) $>35–40$ mmHg.

Systemic Reperfusion & Catheter Interventions

Therapeutic Anticoagulation Regimens

Initiate anticoagulation for confirmed PE unless contraindicated. If PE is strongly suspected and imaging is delayed, consider empiric therapeutic anticoagulation when bleeding risk is low.

1. Unfractionated Heparin (UFH) IV: An option when rapid titration/reversal or severe renal impairment favors it; instability or a planned intervention does not automatically make UFH preferred.
   • Dosing: A common weight-based regimen is 80 units/kg IV, then 18 units/kg/hr, adjusted using the local nomogram.
   • Targets: Anti-Xa 0.3–0.7 IU/mL or the laboratory-calibrated therapeutic aPTT range.
2. Low-Molecular-Weight Heparin (LMWH): Preferred over UFH for initial parenteral therapy in AHA/ACC Categories C1–E1, including many procedural candidates. Enoxaparin 1 mg/kg SC q12h (or 1.5 mg/kg daily); reduce to 1 mg/kg daily if CrCl $<30$ mL/min, with renal/bleeding reassessment.
3. DOACs: First-line in stable low/intermediate-low PE. Apixaban (10 mg PO BID x 7d, then 5 mg BID) and Rivaroxaban (15 mg PO BID for 21 days, then 20 mg daily; take each dose with food) require no parenteral lead-in. Dabigatran and Edoxaban require $\ge 5$ days parenteral lead-in.

Acute Cor Pulmonale & Pulmonary Hypertension Crises

Acute cor pulmonale is acute RV failure from sudden surges in pulmonary vascular resistance (PVR; normal 50–250 dynes·sec/cm$^5$).

The RV Ischemia Death Spiral

The thin-walled RV is intolerant of sudden afterload spikes. Normal right coronary artery (RCA) perfusion occurs in both systole and diastole. Severe PVR increases RV systolic pressure, causing dilation, tricuspid regurgitation, and leftward septal shift ("D-shaped" LV). This restricts LV filling, reducing cardiac output and MAP. As aortic root pressure declines and RV intracavitary pressure climbs, right ventricular coronary perfusion pressure collapses: $CPP_{RV} = \text{Aortic Diastolic Pressure} - \text{RV End-Diastolic Pressure}$ This produces severe RV ischemia, leading to circulatory arrest (PEA).

Triggers & Hemodynamic Management

• Triggers: Hypoxia ($PaO_2 <60$ mmHg), hypercapnia/acidemia ($pH <7.30$, $PaCO_2 >45$), hypothermia, agitation, and excessive PEEP ($>10\text{ cmH}_2\text{O}$).
• Maintain Perfusion Pressure: Titrate norepinephrine (0.05–0.5 mcg/kg/min) as first-line vasopressor to maintain MAP $\ge 65–70$ mmHg, preserving $CPP_{RV}$ without increasing PVR. Cautiously add dobutamine (2.5–10 mcg/kg/min) or milrinone (0.25–0.75 mcg/kg/min; with vasopressor) for RV inotropic support.
• Strict Fluid Restraint: Avoid aggressive crystalloid boluses; fluid overdistends the failing RV, worsening septal impingement and LV underfilling.
• Inhaled Pulmonary Vasodilators:
  • Inhaled Nitric Oxide (iNO): 20–40 ppm selectively dilates ventilated pulmonary vessels, reducing RV afterload without systemic hypotension.
  • Inhaled Epoprostenol (Veletri): 10–50 ng/kg/min continuous aerosolization provides equivalent selective pulmonary vasodilation.
  • Oral Agents: Treprostinil and oral PDE-5 inhibitors (sildenafil 20 mg PO TID) represent chronic PAH therapy; avoid acute IV loading in shock to prevent systemic collapse.